Clinical trial
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
NCT00454805 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00454805 |
|---|---|
| Title | AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer. |
| Official title | A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Breast Cancer |
| Intervention type | Drug |
| Interventions | AZD2171, Fulvestrant |
| Enrollment | 75 |
| Start date | Mar 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Apr 1, 2016 |
| First posted | Apr 2, 2007 |
| Last update posted | Aug 3, 2016 |
| Countries | Australia, Brazil, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: